Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region
Authors:
- Ronylson José S. SilvaRSRonylson José S. Silva
- Raquel Silva Do NascimentoRNRaquel Silva Do Nascimento
- José Augusto J. Oliveira-NetoJOJosé Augusto J. Oliveira-Neto
- Fabricio Quaresma SilvaFSFabricio Quaresma Silva
- Juliana Nádia F. PiauienseJPJuliana Nádia F. Piauiense
- Camila Moraes GomesCGCamila Moraes Gomes
- Luiz Marcelo L. PinheiroLPLuiz Marcelo L. Pinheiro
- Rafael Lima ResqueRRRafael Lima Resque
- João Renato R. PinhoJoão Renato R. Pinho
- Emil KupekEKEmil Kupek
- Benedikt FischerBFBenedikt Fischer
- Luiz Fernando A. MachadoLMLuiz Fernando A. Machado
Open Access
Abstract
Hepatitis B (HBV) and delta (HDV) viruses are endemic in the Amazon region, but vaccine coverage against HBV is still limited. People who use illicit drugs (PWUDs) represent a high-risk group due to common risk behavior and socioeconomic factors that facilitate the acquisition and transmission of pathogens. The present study assessed the presence of HBV and HBV-HDV co-infection, identified viral sub-genotypes, and verified the occurrence of mutations in coding regions for HBsAg and part of the polymerase in HBV-infected PWUDs in municipalities of the Brazilian states of Amapá and Pará, in the Amazon region. In total, 1074 PWUDs provided blood samples and personal data in 30 municipalities of the Brazilian Amazon. HBV and HDV were detected by enzyme-linked immunosorbent assay and polymerase chain reaction. Viral genotypes were identified by nucleotide sequencing followed by phylogenetic analysis, whereas viral mutations were analyzed by specialized software. High rates of serological (32.2%) and molecular (7.2%) markers for HBV were detected, including cases of occult HBV infection (2.5%). Sub-genotypes A1, A2, D4, and F2a were most frequently found. Escape mutations due to vaccine and antiviral resistance were identified. Among PWUDs with HBV DNA, serological (19.5%) and molecular (11.7%) HDV markers were detected, such as HDV genotypes 1 and 3. These are worrying findings, presenting clear implications for urgent prevention and treatment needs for the carriers of these viruses.Keywords
Funding Information
- Ministério da Saúde/Secretaria de Vigilância em Saúde, Brazil (MS/SVS – TC 318/2013)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ – Proc. 475142/ 2013-6)
This publication has 93 references indexed in Scilit:
- Phylogeography and evolutionary history of hepatitis B virus genotype F in BrazilVirology Journal, 2013
- Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patientsBMC Microbiology, 2012
- Hepatitis delta virusThe Lancet, 2011
- A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisationsBMC Public Health, 2011
- Hepatitis B virus resistance to antiviral drugs: where are we going?Liver International, 2011
- Differential Impact of Immune Escape Mutations G145R and P120T on the Replication of Lamivudine-Resistant Hepatitis B Virus e Antigen-Positive and -Negative StrainsJournal of Virology, 2010
- High frequency of SEN virus infection in thalassemic patients and healthy blood donors in IranVirology Journal, 2010
- Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolatesBMC Microbiology, 2007
- RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed modelsBioinformatics, 2006
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994